Virginia Bio, the premier statewide non-profit association representing the life science industry in the Commonwealth of Virginia, has elected two new members to their Board of Directors for a term of three years. The election took place on December 14, 2017 at the Virginia Bio Annual Membership meeting in Richmond, Virginia. The new directors will begin their terms effective on January 1, 2018.
NexImmune, an emerging leader in the field of antigen-directed immunotherapy, announced the closing of a Series A financing co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital, along with significant participation from Piedmont Capital Partners. In conjunction with the financing, Tony Yao, MD, PhD, a Partner at ArrowMark Partners, will join NexImmune’s Board of Directors.
George Davis, CEO of the Maryland Technology Development Corporation (TEDCO), joins Rich Bendis to discuss the Economic Development Balance, Goals for Business in the State, and the Partnership across the Region.
Listen now on iTunes , Google Play , and TuneIn.
Ashish K. Kulkami, PhD of Avantor, Anne S. Lindblad, PhD of The Emmes Corporation, and Kurt Newman, MD of Children’s National Health System, Join BHI’s Board
BioHealth Innovation, Inc. (BHI) announced that its Board of Directors has unanimously approved the appointments of three new board members, Ashish K. Kulkarni, PhD, Executive Vice President and Chief Technology Officer of Avantor, Anne S. Lindblad, PhD, President and CEO, The Emmes Corporation, and Kurt Newman, MD, President and Chief Executive Officer, Children’s National Health System.